放射性肺炎研究进展  

Research progress of radiation pneumonitis

作　　者：陈诚[1] 李建成[1] 

机构地区：[1]福建医科大学教学医院福建省肿瘤医院放疗科,福州350014

出　　处：《国际肿瘤学杂志》2011年第11期849-852,共4页Journal of International Oncology

摘　　要：放射性肺炎（RP）影响肺癌放疗剂量的提高并导致患者生活质量下降。基于分子水平的研究进展，多细胞因子介导的多细胞参与RP的发生机制越来越受人关注，基因多态性的研究也证实不同种群RP的发生机制可能存在差异；而更多研究探讨了物理指标V20、平均肺剂量及生物指标转化生长因子-β（TGF—β）等的临床预测价值。治疗上要注意肺毒性的药物，推广放疗新技术。药物预防方面，针对正常组织放射性损伤的靶分子是目前研究的热点。Radiation pneumonitis （RP） is one of the most common toxicities in patients with lung cancer treated by radiotherapy, which limits the delivered dose and may thus hampers tumor control, then lowers the patients, life quality. Based on the progress of molecular biology, RP may be regarded as a continu- ous progression of events induced by various cytokines involving numerous eells. Researches on gene polymor- phisms indicate different mechanisms in the pathogenesis of RP among different races. Besides, more studies focus on the predictive value of dosimetric parameters such as V20 ,mean lung dose（MLD） and biological markers such as transforming growth factor-β （ TGF-β）. Decreasing use of drugs which may exacerbate RP and increasing use of modem treatments may be beneficial in the prevention. Meanwhile as the respect of drug prevention, more and more emphases are being placed on the target molecule of radiation-induced injury.

关 键 词：肺肿瘤 放射疗法 放射性肺炎 

分 类 号：R734.2[医药卫生—肿瘤]